INTCO MEDICAL(300677) Sou Hu Cai Jing·2025-05-24 08:54Core Points - The company reported a revenue of 9.523 billion yuan for 2024, representing a year-on-year growth of 37.65%, and a net profit of 1.465 billion yuan, which is an increase of 282.63% compared to the previous year [2][7] - The company achieved a capacity utilization rate of 100% and focused on optimizing market layout to gain more market share, leading to significant performance growth [2][3] - The company is facing an 80% tariff on medical-grade nitrile gloves, a 55% tariff on industrial-grade nitrile gloves, and a 30% tariff on PVC gloves in the U.S. market, which accounts for approximately 30%-35% of its overseas revenue [4][7] Performance Disclosure - For 2024, the company reported a revenue of 9.523 billion yuan, a 37.65% increase year-on-year, and a net profit of 1.465 billion yuan, reflecting a 282.63% growth compared to the previous year [2][7] - The company maintained a capacity utilization rate of 100%, indicating strong operational efficiency [2] Institutional Research - During the performance briefing on May 19, the company attributed its 2024 growth to improved supply-demand dynamics in the disposable glove industry and increased sales prices compared to 2023 [3] - The company is leveraging its production, capital, and sales channel advantages to capture a larger market share [3] Company Announcements - The company has repurchased 2,523,900 shares, accounting for 0.3906% of its total share capital, with a total transaction amount of approximately 53.52 million yuan [5] - The company plans to distribute a total cash dividend of approximately 269.61 million yuan for 2024, which represents 18.40% of the net profit attributable to shareholders [6] - The company is adjusting its 2022 restricted stock incentive plan's performance assessment indicators due to geopolitical complexities and trade friction risks, which will be submitted for shareholder approval [8]